Some clinical studies have investigated ctDNA mutations associated with targeted therapy response in patients with HER2-positive breast cancer and endocrine therapy response in patients with ER-positive metastatic breast cancer [55,56]. The gene discussed is ERBB2; the disease is breast carcinoma.